Ulka Vaishampayan, MD

Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment

ByUlka Vaishampayan, MD,Alan Tan, MD,Laurence Albiges, MD, PhD,Neeraj Agarwal, MD,Matthew T. Campbell, MD, MS,Benjamin Maughan, MD, PharmD

December 19th 2023

Leading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.

Triple Combination Therapies in RCC: Clinical Trial Insights

ByUlka Vaishampayan, MD,Alan Tan, MD,Laurence Albiges, MD, PhD,Neeraj Agarwal, MD,Matthew T. Campbell, MD, MS,Benjamin Maughan, MD, PharmD

December 19th 2023

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing

ByUlka Vaishampayan, MD,Alan Tan, MD,Laurence Albiges, MD, PhD,Neeraj Agarwal, MD,Matthew T. Campbell, MD, MS,Benjamin Maughan, MD, PharmD

December 12th 2023

Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.

Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma

ByUlka Vaishampayan, MD,Alan Tan, MD,Laurence Albiges, MD, PhD,Neeraj Agarwal, MD,Matthew T. Campbell, MD, MS,Benjamin Maughan, MD, PharmD

December 12th 2023

Expert insight into how to discuss and manage treatment-related toxicities with cancer patients and their families, emphasizing the importance of early communication and vigilance.

Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

ByUlka Vaishampayan, MD,Alan Tan, MD,Laurence Albiges, MD, PhD,Neeraj Agarwal, MD,Matthew T. Campbell, MD, MS,Benjamin Maughan, MD, PharmD

December 5th 2023

Expert oncologists discuss the nuances of managing toxicities associated with Cabozantinib and Nivolumab combination therapy for advanced renal cell carcinoma (RCC).

Sequencing and Second-Line Therapy in RCC: Patient Scenario

ByUlka Vaishampayan, MD,Alan Tan, MD,Laurence Albiges, MD, PhD,Neeraj Agarwal, MD,Matthew T. Campbell, MD, MS,Benjamin Maughan, MD, PharmD

December 5th 2023

Expert oncologists discuss the challenges and considerations in choosing second-line therapy for a patient with metastatic renal cell carcinoma (RCC) in a case-based context.

Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC

ByUlka Vaishampayan, MD,Alan Tan, MD,Laurence Albiges, MD, PhD,Neeraj Agarwal, MD,Matthew T. Campbell, MD, MS,Benjamin Maughan, MD, PharmD

November 28th 2023

Renowned oncologists discuss critical factors influencing their decisions for frontline therapy in metastatic renal cell carcinoma (RCC), including risk assessment, sites of metastasis, performance status, and treatment goals.

Comparing Treatment Combinations in Renal Cell Carcinoma

ByUlka Vaishampayan, MD,Alan Tan, MD,Laurence Albiges, MD, PhD,Neeraj Agarwal, MD,Matthew T. Campbell, MD, MS,Benjamin Maughan, MD, PharmD

November 28th 2023

A comprehensive discussion on VEGF-TKI-based combinations and immune checkpoint inhibitor combinations in the treatment of renal cell carcinoma, featuring key clinical trial results and treatment strategies.

Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma

ByUlka Vaishampayan, MD,Alan Tan, MD,Laurence Albiges, MD, PhD,Neeraj Agarwal, MD,Matthew T. Campbell, MD, MS,Benjamin Maughan, MD, PharmD

November 21st 2023

Expert panelists review the management of non-clear cell histology in renal cell carcinoma, exploring treatment options, clinical trials, and the potential role of immune checkpoint inhibitors.

Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen

ByUlka Vaishampayan, MD,Alan Tan, MD,Laurence Albiges, MD, PhD,Neeraj Agarwal, MD,Matthew T. Campbell, MD, MS,Benjamin Maughan, MD, PharmD

November 21st 2023

Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.

Imaging and Staging Considerations in Renal Cell Carcinoma

ByUlka Vaishampayan, MD,Alan Tan, MD,Laurence Albiges, MD, PhD,Neeraj Agarwal, MD,Matthew T. Campbell, MD, MS,Benjamin Maughan, MD, PharmD

November 14th 2023

Key opinion leaders discuss the use of brain MRI and bone assessment in the staging and monitoring of patients with renal cell carcinoma.

Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

ByUlka Vaishampayan, MD,Alan Tan, MD,Laurence Albiges, MD, PhD,Neeraj Agarwal, MD,Matthew T. Campbell, MD, MS,Benjamin Maughan, MD, PharmD

November 14th 2023

Renowned oncologists discuss the case of a 75-year-old man with advanced renal cell carcinoma, providing insights into evaluation and frontline therapy choices.

Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

ByUlka Vaishampayan, MD,Laurence Albiges, MD, PhD,Neeraj Agarwal, MD,Matthew T. Campbell, MD, MS,Benjamin Maughan, MD, PharmD,Alan Tan, MD

October 30th 2023

Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.

CAR T-Cell Therapy in Metastatic CRPC and Future Directions in Care

ByRana R. McKay, MD, University of California San Diego Medical Center,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD

August 29th 2023

Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.

Ongoing Clinical Trials in the Metastatic CRPC Setting

ByRana R. McKay, MD, University of California San Diego Medical Center,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD

August 29th 2023

Key opinion leaders in metastatic castration-resistant prostate cancer share insight to key ongoing clinical trials within the landscape.

Potential for CDK4/6 Inhibitors in Metastatic CRPC

ByRana R. McKay, MD, University of California San Diego Medical Center,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD

August 22nd 2023

Expert panelists briefly reflect on clinical trial data with CDK4/6 inhibitors in metastatic castration-resistant prostate cancer and how their role in this setting might evolve.

Novel Therapeutic Targets in Metastatic CRPC

ByRana R. McKay, MD, University of California San Diego Medical Center,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD

August 22nd 2023

A broad discussion on emerging therapeutic targets in metastatic castration-resistant prostate cancer and where they may fall within the treatment landscape.

Metastatic CRPC: Novel Treatment Strategies With Radioligand Therapy

ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD

August 15th 2023

Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.

Radioligands in the Treatment of Metastatic CRPC: Radium-223

ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD

August 15th 2023

Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.

Radioligands in the Treatment of Metastatic CRPC: Lutetium-177–PSMA-617

ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD

August 8th 2023

Focused discussion on the role of lutetium-177–PSMA-617 as radioligand therapy in patients with metastatic castration-resistant prostate cancer.

Combination PARPi Strategies in Metastatic CRPC: Interpreting Data From Clinical Trials

ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD

August 8th 2023

Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.

Advent of PARP Inhibitors in Metastatic CRPC

ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD

August 1st 2023

Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.

Evolving Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer

ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD

August 1st 2023

Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.

Informing Systemic Therapy Selection With Negative Data in HSPC

ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD

July 25th 2023

A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.

What is the Role of Locoregional Therapy in Metastatic HSPC?

ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD

July 25th 2023

Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.

Systemic Treatment Armamentarium in Metastatic HSPC

ByRana R. McKay, MD, University of California San Diego Medical Center,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD

June 26th 2023

Shared insight on the range of systemic therapy options available to patients who present with metastatic hormone-sensitive prostate cancer.

Overview of Metastatic HSPC: Diagnosis and Risk Stratification

ByRana R. McKay, MD, University of California San Diego Medical Center,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD,Arash Rezazadeh Kalebasty, MD

June 26th 2023

Opening their first module on metastatic hormone-sensitive prostate cancer, panelists consider optimal diagnostic and risk stratification strategies for when a patient presents in clinic.

Future Directions in the Management of Renal Cell Carcinoma

ByThomas Powles, MD,Rana R. McKay, MD,Ulka Vaishampayan, MD,Eric Jonasch, MD,Benjamin Maughan, MD

November 10th 2022

Shared insight on the evolving treatment landscape of renal cell carcinoma and expectations for future evolution in the paradigm.

Novel Treatment Strategies in Non-Clear Cell Renal Cell Carcinoma

ByThomas Powles, MD,Rana R. McKay, MD,Ulka Vaishampayan, MD,Eric Jonasch, MD,Benjamin Maughan, MD

November 10th 2022

Before closing out there review of non–clear cell RCC management, expert oncologists highlight novel therapeutic strategies and ongoing clinical trials.

Systemic Therapy in the Treatment of Non-Clear Cell RCC: The Evolving Landscape

ByThomas Powles, MD,Rana R. McKay, MD,Ulka Vaishampayan, MD,Eric Jonasch, MD,Benjamin Maughan, MD

November 3rd 2022

Moving on to discuss the management of non–clear cell renal cell carcinoma, panelists consider cornerstone treatment options in this setting.

Articles by Ulka Vaishampayan, MD

Key Takeaways: Advancements and Challenges in Kidney Cancer Treatment

Triple Combination Therapies in RCC: Clinical Trial Insights

Novel Therapies for Advanced RCC: LITESPARK-005 and Treatment Sequencing

Navigating Toxicity Discussions With Patients With Renal Cell Carcinoma

Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

Sequencing and Second-Line Therapy in RCC: Patient Scenario

Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC

Comparing Treatment Combinations in Renal Cell Carcinoma

Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma

Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen

Imaging and Staging Considerations in Renal Cell Carcinoma

Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

CAR T-Cell Therapy in Metastatic CRPC and Future Directions in Care

Ongoing Clinical Trials in the Metastatic CRPC Setting

Potential for CDK4/6 Inhibitors in Metastatic CRPC

Novel Therapeutic Targets in Metastatic CRPC

Metastatic CRPC: Novel Treatment Strategies With Radioligand Therapy

Radioligands in the Treatment of Metastatic CRPC: Radium-223

Radioligands in the Treatment of Metastatic CRPC: Lutetium-177–PSMA-617

Combination PARPi Strategies in Metastatic CRPC: Interpreting Data From Clinical Trials

Advent of PARP Inhibitors in Metastatic CRPC

Evolving Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer

Informing Systemic Therapy Selection With Negative Data in HSPC

What is the Role of Locoregional Therapy in Metastatic HSPC?

Systemic Treatment Armamentarium in Metastatic HSPC

Overview of Metastatic HSPC: Diagnosis and Risk Stratification

Future Directions in the Management of Renal Cell Carcinoma

Novel Treatment Strategies in Non-Clear Cell Renal Cell Carcinoma

Systemic Therapy in the Treatment of Non-Clear Cell RCC: The Evolving Landscape

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma